KIRKLAND, Wash., Feb. 28, 2013 (GLOBE NEWSWIRE) -- Talyst, the leader in 340B splitting solutions, offers a variety of solutions to support the recent Health Resources and Services Administration (HRSA) policy issued February 7, 2013.
The policy clarifies the 340B Drug Pricing Program's ruling regarding the statutory prohibition against obtaining covered outpatient drugs through a group purchasing organization (GPO) for certain covered entities. The new policy will be in effect after April 7, 2013.
To support health systems and hospitals with 340B compliance and auditing, Talyst offers a variety of 340B splitting solutions, including AutoSplit 340B Software and AutoSplit 340B Fully-Managed. Talyst's AutoSplit 340B Fully Managed Solution has Talyst's experts manage the entire 340B program including audits and compliance reports.
"We are aggressively ensuring our customers are compliant to the HRSA policy release 2013-1," said George Puckett, General Manager of 340B Pharmacy Services at Talyst. "Talyst supports three-way splitting, including WAC accounts to ensure our customers are audit ready."
For more information, please visit HRSA or Talyst.com.
Talyst is a leader in pharmacy automation and engineers the safer pharmacy. Our solutions provide enterprise-wide medication management across your entire health system to offer greater inventory control, enhanced workflow efficiency, and improved patient safety. As of 2013, Talyst has installed automated solutions in more than 600 integrated healthcare systems, acute-care hospitals, long-term care facilities, and correctional institutions. We offer a powerful software platform with a suite of hardware components to meet your enterprise-wide needs. Follow us on Twitter @Talyst_Inc or visit us at www.talyst.com.
The Talyst logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=17366
CONTACT: Linh Dinh 425.289.5732